These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 26780304)
1. From Sphingosine Kinase to Dihydroceramide Desaturase: A Structure-Activity Relationship (SAR) Study of the Enzyme Inhibitory and Anticancer Activity of 4-((4-(4-Chlorophenyl)thiazol-2-yl)amino)phenol (SKI-II). Aurelio L; Scullino CV; Pitman MR; Sexton A; Oliver V; Davies L; Rebello RJ; Furic L; Creek DJ; Pitson SM; Flynn BL J Med Chem; 2016 Feb; 59(3):965-84. PubMed ID: 26780304 [TBL] [Abstract][Full Text] [Related]
2. Proteasomal degradation of sphingosine kinase 1 and inhibition of dihydroceramide desaturase by the sphingosine kinase inhibitors, SKi or ABC294640, induces growth arrest in androgen-independent LNCaP-AI prostate cancer cells. McNaughton M; Pitman M; Pitson SM; Pyne NJ; Pyne S Oncotarget; 2016 Mar; 7(13):16663-75. PubMed ID: 26934645 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of dihydroceramide desaturase activity by the sphingosine kinase inhibitor SKI II. Cingolani F; Casasampere M; Sanllehí P; Casas J; Bujons J; Fabrias G J Lipid Res; 2014 Aug; 55(8):1711-20. PubMed ID: 24875537 [TBL] [Abstract][Full Text] [Related]
4. A novel mode of action of the putative sphingosine kinase inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl) thiazole (SKI II): induction of lysosomal sphingosine kinase 1 degradation. Ren S; Xin C; Pfeilschifter J; Huwiler A Cell Physiol Biochem; 2010; 26(1):97-104. PubMed ID: 20502009 [TBL] [Abstract][Full Text] [Related]
5. Development of SKI-349, a dual-targeted inhibitor of sphingosine kinase and microtubule polymerization. Hengst JA; Hegde S; Paulson RF; Yun JK Bioorg Med Chem Lett; 2020 Oct; 30(20):127453. PubMed ID: 32736077 [TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of 2-epi-jaspine B analogs as selective sphingosine kinase 1 inhibitors. Yang H; Li Y; Chai H; Yakura T; Liu B; Yao Q Bioorg Chem; 2020 May; 98():103369. PubMed ID: 31703810 [TBL] [Abstract][Full Text] [Related]
7. The sphingosine kinase inhibitor 2-(p-hyroxyanilino)-4-(p-chlorophenyl)thiazole reduces androgen receptor expression via an oxidative stress-dependent mechanism. Tonelli F; Alossaimi M; Williamson L; Tate RJ; Watson DG; Chan E; Bittman R; Pyne NJ; Pyne S Br J Pharmacol; 2013 Mar; 168(6):1497-505. PubMed ID: 23113536 [TBL] [Abstract][Full Text] [Related]
8. Field template-based design and biological evaluation of new sphingosine kinase 1 inhibitors. Alshaker H; Srivats S; Monteil D; Wang Q; Low CMR; Pchejetski D Breast Cancer Res Treat; 2018 Nov; 172(1):33-43. PubMed ID: 30043096 [TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of sphingosine kinase inhibitors. French KJ; Upson JJ; Keller SN; Zhuang Y; Yun JK; Smith CD J Pharmacol Exp Ther; 2006 Aug; 318(2):596-603. PubMed ID: 16632640 [TBL] [Abstract][Full Text] [Related]
10. Discovery and evaluation of inhibitors of human sphingosine kinase. French KJ; Schrecengost RS; Lee BD; Zhuang Y; Smith SN; Eberly JL; Yun JK; Smith CD Cancer Res; 2003 Sep; 63(18):5962-9. PubMed ID: 14522923 [TBL] [Abstract][Full Text] [Related]
11. Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives as EGFR TK inhibitors and potential anticancer agents. Lv PC; Li DD; Li QS; Lu X; Xiao ZP; Zhu HL Bioorg Med Chem Lett; 2011 Sep; 21(18):5374-7. PubMed ID: 21802290 [TBL] [Abstract][Full Text] [Related]
12. A Novel Selective Sphingosine Kinase 2 Inhibitor, HWG-35D, Ameliorates the Severity of Imiquimod-Induced Psoriasis Model by Blocking Th17 Differentiation of Naïve CD4 T Lymphocytes. Shin SH; Kim HY; Yoon HS; Park WJ; Adams DR; Pyne NJ; Pyne S; Park JW Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33171607 [TBL] [Abstract][Full Text] [Related]
13. Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation. Diab S; Teo T; Kumarasiri M; Li P; Yu M; Lam F; Basnet SK; Sykes MJ; Albrecht H; Milne R; Wang S ChemMedChem; 2014 May; 9(5):962-72. PubMed ID: 24677692 [TBL] [Abstract][Full Text] [Related]
14. Synthesis of some new pyrazole-based 1,3-thiazoles and 1,3,4-thiadiazoles as anticancer agents. Dawood KM; Eldebss TM; El-Zahabi HS; Yousef MH; Metz P Eur J Med Chem; 2013; 70():740-9. PubMed ID: 24231309 [TBL] [Abstract][Full Text] [Related]
15. Characterization of isoenzyme-selective inhibitors of human sphingosine kinases. Gao P; Peterson YK; Smith RA; Smith CD PLoS One; 2012; 7(9):e44543. PubMed ID: 22970244 [TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and in vitro antiproliferative activity of novel Dasatinib derivatives. Cai J; Zhang S; Zheng M; Wu X; Chen J; Ji M Bioorg Med Chem Lett; 2012 Jan; 22(2):806-10. PubMed ID: 22217877 [TBL] [Abstract][Full Text] [Related]
18. Assessment of the effect of sphingosine kinase inhibitors on apoptosis,unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics. Evangelisti C; Evangelisti C; Teti G; Chiarini F; Falconi M; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Beak DJ; Bittman R; Pyne S; Pyne NJ; Martelli AM Oncotarget; 2014 Sep; 5(17):7886-901. PubMed ID: 25226616 [TBL] [Abstract][Full Text] [Related]
19. Development of a sphingosine kinase 1 specific small-molecule inhibitor. Hengst JA; Wang X; Sk UH; Sharma AK; Amin S; Yun JK Bioorg Med Chem Lett; 2010 Dec; 20(24):7498-502. PubMed ID: 21050755 [TBL] [Abstract][Full Text] [Related]
20. Synthesis and Biological Evaluation of BODIPY-PF-543. Shrestha J; Hwang GT; Lee T; Kim SW; Oh YS; Kwon Y; Hong SW; Kim S; Seop Moon H; Baek DJ; Park EY Molecules; 2019 Dec; 24(23):. PubMed ID: 31810327 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]